Circulating tumor cells (CTCs) - clinical significance in patients: With ovarian cancer;Krążące komórki nowotworowe - znaczenie kliniczne u chorych na raka jajnika

Ginekologia Polska

Volumn 83, Issue 4, 2012, Pages 291-294

  Magnowski, Piotr ^a   Bochyński, Hubert ^a   Nowak Markwitz, Ewa ^a   Zabel, Maciej ^b   Spaczyński, Marek ^a  

^a Klinika Onkologii Ginekologicznej   (Poland)

^b Uniwersytetu Medycznego w Poznaniu   (Poland)

Author keywords

Chemotherapy; Circulating tumor cells; Ovarian cancer

Indexed keywords

ADULT; BLOOD; CANCER INVASION; CANCER STAGING; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; METASTASIS; OVARY TUMOR; PATHOLOGY; REVIEW; SURVIVAL RATE; TUMOR EMBOLISM; WOMEN'S HEALTH;

ADULT; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; OVARIAN NEOPLASMS; SURVIVAL RATE; WOMEN'S HEALTH;

EID: 84862003200     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Synowiec A, Wcisło G, Bodnar L, [et al.]. Surgical treatment in ovarian cancer prevention in carriers of the BRCA1/BRCA2 mutation. Ginekol Pol. 2012, 83, 51-56.
2. http://85.128.14.124/krn/std_zach_rozp/default.asp.
3. Roett M, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009, 80, 609-616.
4. SEER: Surveillance, Epidemiology and End Results Program 2004.
5. Ashworth T. A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aus Med J. 1869, 14, 146-149.
6. Maheswaran S, Haber D. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010, 20, 96-99.
7. Ruiter D, van Krieken J, van Muijen G, et al. Tumor metastasis: is tissue an issue? The Lancet Oncology. 2001, 2, 109-112.
8. Patent FDA. Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. Fed Regist. 2004, 69, 26036-26038.
9. Sieuwerts A, Kraan J, Bolt J, [et al.]. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst. 2009, 101, 61-66.
10. Miller M, Doyle G, Terstappen L. Significance of circulating tumor cells detected by the CellSearch System in patients with metastatic breast colorectal and prostate cancer. J Oncol. 2010, 2010, 617421.
11. Nagrath S, Sequist L, Maheswaran S, [et al.]. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007, 450, 1235-1239.
12. Butler T, Gullino P. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res. 1975, 35, 512-516.
13. Cristofanilli M, Hayes D, Budd G, [et al.]. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol. 2005, 23, 1420-1430.
14. Cohen S, Alpaugh R, Gross S, [et al.]. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2006, 6, 125-132.
15. Moreno J, Miller M, Gross S, [et al.]. Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology. 2005, 65, 713-718.
16. Krivacic R, Ladanyi A, Curry D, [et al.]. A rare-cell detector for cancer. Proc Natl Acad Sci USA. 2004, 101, 10501-10504.
17. Cain J, Ellis G, Collins C, [et al.]. Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment. Gynecol Oncol. 1990, 38, 442-445.
18. Marth C, Kisic J, Kaern J, [et al.]. Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis. Cancer. 2002, 94, 707-712.
19. Judson P, Geller M, Bliss R, [et al.]. Preoperative detection of peripherally circulating cancer cells and its prognosis significance in ovarian cancer. Gynecol Oncol. 2003, 91, 389-394.
20. Schindlbeck C, Hantschmann P, Zerzer M, [et al.]. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase II alpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow. Int J Gynecol Cancer. 2007, 17, 1047-1055.
21. He W, Kularatne S, Kalli K, [et al.]. Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands. Int J Cancer. 2008, 123, 1968-1973.
22. Obermayr E, Sanchez-Cabo F, Tea M, [et al.]. Assesment of six gene panel for the molekular detection of circulating tumor cells in the blood of female cancer patients. BMC Cancer. 2010, 10, 666.
23. Fehm T, Becker S, Bachmann C, [et al.]. Detecting of disseminated tumor cells in patients with gynecological cancers. Gynecol Oncol. 2006, 103, 942-947.
24. Fan T, Zhao Q, Chen J, [et al.]. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol. 2009, 112, 185-191.
25. Wimberger P, Heubner M, Otterbach F, [et al.]. Influence of platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with ovarian cancer. Gynecol Oncol. 2007, 107, 331-338.
26. Banys M, Solomayer E, Becker S, [et al.]. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic malignances. Int J Gynecol Cancer. 2009, 19, 948-952.